Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)-Reference-Cited by-同舟云学术

Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV)

Published:2020-07-22 Issue:11 Volume:72 Page:2032-2034
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Bekker Adrie¹,Decloedt Eric H²,Slade Gretchen¹,Cotton Mark F¹,Rabie Helena¹,Cressey Tim R³⁴⁵

Affiliation:

1. Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

2. Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

3. PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand

4. Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom

5. Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

Abstract

Abstract Abacavir is a potential option for prophylaxis and early treatment of human immunodeficiency virus (HIV), but no data are available in neonates. Ten neonates administered a single abacavir dose of 8 mg/kg before 15 days of life had substantially higher exposures than those reported in infants and children, with no reported adverse events.

Funder

Collaborative Initiative for Pediatric HIV Education and Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa1026/33795972/ciaa1026.pdf

Reference12 articles.

1. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1;Kasirye;Clin Pharmacol Ther,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial;The Lancet HIV;2024-02

2. Current drugs for HIV-1: from challenges to potential in HIV/AIDS;Frontiers in Pharmacology;2023-10-26

3. Updates in the Approach to Pediatric HIV Care and Prevention;Current Treatment Options in Pediatrics;2023-10-13

4. Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands;Journal of the Pediatric Infectious Diseases Society;2023-10-05

5. Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts;Antiviral Therapy;2023-04